Text Size
46 studies found for:    " September 07, 2011":" October 07, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
" September 07, 2011":" October 07, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
Conditions: Human Immunodeficiency Virus (HIV);   HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Maraviroc
2 Not yet recruiting A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
Conditions: Human Immunodeficiency Virus (HIV);   HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Raltegravir
3 Recruiting Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Cobicistat;   Drug: Darunavir
4 Not yet recruiting Efficiency of the Hepatitis B Sci-B-Vac Vaccine in HIV Positive Patients
Condition: HIV
Intervention: Biological: Sci-B-Vac
5 Recruiting Improving Uptake of Early Infant Diagnosis of HIV for the Prevention of Mother-to-child Transmission of HIV
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome
Intervention: Other: Text message
6 Recruiting Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)
Conditions: HIV Infection;   Hepatitis C
Intervention: Behavioral: Contigent voucher incentive (CVI)
7 Recruiting Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
Condition: HIV Infection
Intervention: Drug: Polyphenon E
8 Recruiting A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
Condition: HIV Infection
Interventions: Biological: HIV-1 Tat/delta-V2 Env combined vaccine;   Biological: HIV-1 delta-V2 Env vaccine;   Biological: HIV-1 Tat vaccine
9 Active, not recruiting Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure
Condition: Human Immunodeficiency Virus (HIV)
Intervention: Behavioral: Enhanced Treatment Support (ETS)
10 Active, not recruiting Vitamin D Supplementation in HIV
Condition: HIV-infection/Aids
Interventions: Dietary Supplement: Vitamin D3;   Dietary Supplement: Placebo
11 Recruiting Implementation of Nucleic Acid Amplification Testing Screening to Identify Acute and Early HIV Infection
Condition: Acute HIV Infection
Intervention: Other: Nucleic Acid Amplification Testing
12 Completed The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort -
Condition: HIV-1-Associated Cognitive Motor Complex
Intervention:
13 Recruiting Maternal-fetal CD4 Microchimerism in HiV Exposed Newborns After Spontaneous Delivery and Cesarean Section
Condition: Human Immunodeficiency Virus
Intervention:
14 Not yet recruiting Dimiracetam in Painful Neuropathies Affecting AIDS Patients
Condition: Acquired Immunodeficiency Syndrome
Interventions: Drug: Dimiracetam;   Drug: Dimiracetam 25 mg
15 Recruiting Reducing Cardiovascular Disease (CVD) Risk in HIV on Antiretroviral Therapy Over 12 Months
Conditions: HIV-1 Infection;   Cardiovascular Disease
Interventions: Other: Control;   Other: Intervention Group
16 Recruiting The Effect of Probiotics in HIV-1 Infection
Condition: HIV-1 Infection
Interventions: Dietary Supplement: Multi-strain probiotic;   Dietary Supplement: Placebo;   Other: Control
17 Recruiting Renal Transplantation and Raltegravir in HIV-Infected Patients
Conditions: HIV-1 Infection;   Chronic Renal Insufficiency
Intervention: Drug: Raltegravir
18 Completed Etravirine Plus 2 Analogs in HIV-infected Patients
Condition: HIV-1-infection
Intervention:
19 Active, not recruiting Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg OAD;   Drug: darunavir 800mg OAD;   Drug: ritonavir 100mg OAD
20 Recruiting Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Conditions: Human Immunodeficiency Virus Infection;   Hepatitis C
Intervention:
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years